Novozymes A/S (NVZMF)
OTC: NVZMF
· Real-Time Price · USD
67.38
0.00 (0.00%)
At close: Aug 12, 2025, 3:54 PM
Novozymes A/S Income Statement
Financials in EUR. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.08B | 2B | 6.83B | 6.83B | 4.6B | 4.46B | 4.22B | 4.62B | 4.53B | 4.37B | 4.29B | 4.37B | 3.83B | 3.76B | 3.58B | 3.78B |
Cost of Revenue | 483.3M | 959.3M | 3.97B | 3.97B | 2.12B | 2.06B | 1.88B | 2.12B | 2.11B | 2.02B | 1.91B | 1.94B | 1.69B | 1.58B | 1.48B | 1.58B |
Gross Profit | 594.3M | 1.04B | 2.86B | 2.86B | 2.48B | 2.4B | 2.34B | 2.5B | 2.42B | 2.35B | 2.38B | 2.43B | 2.15B | 2.18B | 2.1B | 2.2B |
Operating Income | 265.5M | 435.5M | 503.49M | 503.51M | 1.53B | 1.02B | 865M | 1.13B | 1.09B | 1.29B | 1.11B | 1.15B | 805M | 1.09B | 990M | 1.12B |
Interest Income | n/a | n/a | n/a | n/a | n/a | 11M | 38M | 26M | 53M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 244.7M | 327.1M | 335.66M | 335.67M | 923M | 1.15B | 798M | 1.04B | 1.04B | 1.39B | 1.05B | 1.08B | 771M | 1.05B | 993M | 1.11B |
Net Income | 186M | 241.9M | 238.32M | 238.33M | 698M | 936M | 606M | 784M | 883M | 1.15B | 809M | 832M | 625M | 842M | 794M | 885M |
Selling & General & Admin | 212.3M | 406M | 1.34B | 1.34B | 842M | 767M | 825M | 890M | 803M | 826M | 790M | 804M | 870M | 657M | 631M | 637M |
Research & Development | 107.3M | 218.7M | 725.39M | 725.43M | 524M | 461M | 515M | 517M | 535M | 475M | 498M | 493M | 512M | 435M | 499M | 563M |
Other Expenses | 9.2M | -17.7M | 290.9M | 290.92M | 50M | 148M | n/a | -104M | 196M | -240M | -19M | -12M | n/a | n/a | n/a | n/a |
Operating Expenses | 328.8M | 607M | 2.36B | 2.36B | 1.42B | 1.21B | 1.32B | 1.3B | 1.53B | 1.06B | 1.27B | 1.28B | 1.47B | 1.08B | 1.11B | 1.08B |
Interest Expense | n/a | n/a | n/a | n/a | 30M | n/a | 38M | 111M | 39M | 10M | 71M | 73M | n/a | n/a | 12M | n/a |
Selling & Marketing Expenses | 154M | 290.7M | 970.42M | 970.47M | 601M | 531M | 594M | 639M | 561M | 573M | 552M | 585M | 609M | 456M | 432M | 439M |
Cost & Expenses | 812.1M | 1.57B | 6.33B | 6.33B | 3.53B | 3.27B | 3.21B | 3.42B | 3.64B | 3.08B | 3.18B | 3.23B | 3.15B | 2.67B | 2.59B | 2.66B |
Income Tax Expense | 58.7M | 85.2M | 97.34M | 97.35M | 228M | 219M | 184M | 239M | 168M | 235M | 230M | 237M | 148M | 211M | 199M | 221M |
Shares Outstanding (Basic) | 465M | 456.42M | 277.9M | 277.9M | 278.03M | 277.74M | 277.03M | 277M | 276.5M | 276.3M | 276.31M | 277.1M | 279.08M | 277.1M | 278.3M | 279.2M |
Shares Outstanding (Diluted) | 465M | 456.42M | 277.9M | 277.9M | 278.4M | 277.7M | 277.9M | 277.8M | 278M | 278.4M | 279.4M | 279.5M | 279.6M | 279.8M | 280.7M | 280.9M |
EPS (Basic) | 0.40 | 0.53 | 0.86 | 0.86 | 2.52 | 3.38 | 2.19 | 2.83 | 3.19 | 4.17 | 2.93 | 3.00 | 2.24 | 3.04 | 2.85 | 3.17 |
EPS (Diluted) | 0.40 | 0.53 | 0.86 | 0.86 | 2.51 | 3.37 | 2.18 | 2.82 | 3.18 | 4.14 | 2.90 | 2.98 | 2.24 | 3.01 | 2.83 | 3.15 |
EBITDA | 275.7M | 435.5M | 1.13B | 1.13B | 1.04B | 1.18B | 982M | 1.2B | 1.12B | 1.7B | 1.11B | 1.14B | 824M | 1.09B | 990M | 1.12B |
EBIT | 275.7M | 435.5M | 833.55M | 833.59M | 1.04B | 1.18B | 836M | 1.2B | 1.12B | 1.4B | 1.06B | 1.14B | 824M | 1.09B | 990M | 1.12B |
Depreciation & Amortization | n/a | n/a | 292.31M | 292.25M | 145M | n/a | 335M | 357M | 370M | 377M | 377M | 361M | 345M | 353M | 378M | 340M |